The Zacks Analyst Blog Highlights: Wells Fargo, Broadcom, Gilead, NextEra Energy And Emerson Electric

For Immediate Release

Chicago, IL – July 11, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Wells Fargo (NYSE: WFC – Free Report ), Broadcom (NASDAQ:AVGO) (NASDAQ: AVGO – Free Report ), Gilead (NASDAQ: GILD – Free Report ), NextEra Energy (NYSE:NEE) (NYSE: NEE – Free Report ) and Emerson Electric (NYSE: EMR – Free Report ).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .

Here are highlights from Tuesday’s Analyst Blog:

Top Stock Reports for Today: Wells Fargo, Broadcom & Gilead

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (NYSE: WFC – Free Report ), Broadcom (NASDAQ: AVGO – Free Report ) and Gilead (NASDAQ: GILD – Free Report ). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Wells Fargo ’s shares continue to struggle, reflecting lingering issues pertaining to the customer accounts issue. The stock has gained +1.1% year-to-date, underperforming the Zacks Major Banks industry, which is up +7.5% in the same time period. Wells Fargo lacks investment banking and capital markets assets that have been a source of strength for many of its peers lately.

But the bigger issue for the bank has been the customer accounts issue. Troubles have intensified following the bank’s $190-million settlement last year to resolve regulators’ claims of illegally opening millions of illegal accounts. While the current crisis at the company will take some time to alleviate, the Zacks analyst thinks continued growth in loans and deposits, coupled with cost cuts (the bank plans $4 billion in cost cuts by 2019) should help support results.

Regulatory reform remains another potential macro tailwind, though the timing of any legislative enactments on this front remains uncertain. Notably, Wells Fargo received Fed's approval for its 2017 capital plan.

(You can read the full research report on Wells Fargo here >>> ) .

Shares of Strong Buy rated Broadcom have handily beaten the technology sector as well as the red-hot semiconductor space in the year-to-date period, gaining +35.6%. The Zacks analyst likes the synergistic benefits gained from the merger with Avago, which will drive future profitability.

Seasonal strength in broadband access and sustained cloud data center spending is expected to drive top-line growth in the rest of fiscal 2017. The company recently received U.S. antitrust approval for the buyout of Brocade Communications Systems, which was announced last November and valued at $5.5 billion. However, customer concentration is a significant headwind.

(You can read the full research report on Broadcom here >>> ) .

Gilead ’s shares have been laggards lately, on persistent fears about drug pricing and other regulatory issues that haven't eased up even after the November election. The stock has lost -19.8% of its value over the last year vs. the -0.8% decline for the Zacks Biotech industry.

Gilead’s HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens which now represent 42% of total Gilead HIV prescription volume. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting should also boost sales as the company saw a significant uptick in PrEP usage in 2017.

However, Gilead will lose exclusivity for Viread this year in some countries outside the U.S., which should impact sales. Additionally, the HCV franchise continues to be undercompetitive and pricing pressure is leading to a massive decline in Harvoni and Sovaldi sales.

(You can read the full research report on Gilead here >>> ) .

Other noteworthy reports we are featuring today includeNextEra Energy (NYSE: NEE – Free Report ) and Emerson Electric (NYSE: EMR – Free Report ).

More Stock News: 8 Companies Verge on Apple-Like Run

Did you miss Apple (NASDAQ:AAPL)'s 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade, which could in turn save $200 billion in U.S. healthcare costs.

A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.

Get the full Report on WFC - FREE

Get the full Report on AVGO - FREE

Get the full Report on GILD - FREE

Get the full Report on NEE - FREE

Get the full Report on EMR - FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook (NASDAQ:FB): https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.